PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-2 (2)
 

Clipboard (0)
None

Select a Filter Below

Journals
Authors
more »
Year of Publication
Document Types
1.  Embedded ARM System for Volcano Monitoring in Remote Areas: Application to the Active Volcano on Deception Island (Antarctica) 
Sensors (Basel, Switzerland)  2014;14(1):672-690.
This paper describes the development of a multi-parameter system for monitoring volcanic activity. The system permits the remote access and the connection of several modules in a network. An embedded ARM™™ processor has been used, allowing a great flexibility in hardware configuration. The use of a complete Linux solution (Debian™) as Operating System permits a quick, easy application development to control sensors and communications. This provides all the capabilities required and great stability with relatively low energy consumption. The cost of the components and applications development is low since they are widely used in different fields. Sensors and commercial modules have been combined with other self-developed modules. The Modular Volcano Monitoring System (MVMS) described has been deployed on the active Deception Island (Antarctica) volcano, within the Spanish Antarctic Program, and has proved successful for monitoring the volcano, with proven reliability and efficient operation under extreme conditions. In another context, i.e., the recent volcanic activity on El Hierro Island (Canary Islands) in 2011, this technology has been used for the seismic equipment and GPS systems deployed, thus showing its efficiency in the monitoring of a volcanic crisis.
doi:10.3390/s140100672
PMCID: PMC3926581  PMID: 24451461
ARM; multi-parameter system; volcanic activity; Linux Debian; environmental surveillance
2.  NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial 
Patients treated with vaccines based on NGlycolil gangliosides have showed benefit in progression free survival and overall survival. These molecules, which have been observed in breast cancer cells, are minimally or not expressed in normal human tissue and have been considered as antigen tumor-specific. For this reason they are very attractive to immunotherapy. A phase I/II clinical trial was carried out in metastatic breast cancer patients with the NGlycolylGM3/VSSP vaccine administered by subcutaneous route. Selecting the optimal biological doses of the vaccine in these patients was the principal objective based on the immunogenicity, efficacy and safety results. Six levels of doses of vaccine were studied. Treatment schedule consisted of five doses every two weeks and then monthly until reaching a fifteenth doses. Doses levels studied were 150, 300, 600, 900, 1200 and 1500 μg. Five patients in each level were included except at the 900 μg dose, in which ten patients were included. Immunogenicity was determined by levels of antibodies generated in patients after vaccination. The response criteria of evaluation in solid tumors (RECIST) was used to evaluate antitumoral effect. Safety was evaluated by Common Toxicity Criteria of Adverse Event (CTCAE). The vaccine administration was safe and immunogenic in all does levels. Most frequent adverse events related to vaccination were mild or moderate and were related to injection site reactions and “flu-like” symptoms. Vaccination induced specific anti-NeuGcGM3 IgM and IgG antibodies responses in all patients. Disease control (objective response or stable disease) was obtained in 72.7% of evaluated patients. Median overall survival was 15.9 months. Two patients of two different dose levels achieved overall survival values of about six years. The dose of 900 μg was selected as biological optimal dose in which overall survival was 28.5 months.
doi:10.4137/BCBCR.S8488
PMCID: PMC3465086  PMID: 23055739
metastatic breast cancer; clinical trial; therapeutic vaccine; ganglioside; NGcGM3

Results 1-2 (2)